Last reviewed · How we verify
Standard of Care Antibiotics
Standard of Care Antibiotics is a Antibiotic Small molecule drug developed by Rebiotix Inc.. It is currently in Phase 3 development for Community-acquired pneumonia, Skin and soft tissue infections, Urinary tract infections. Also known as: Antibiotics.
Standard of care antibiotics work by inhibiting bacterial cell wall synthesis or interfering with protein synthesis.
Standard of care antibiotics work by inhibiting bacterial cell wall synthesis or interfering with protein synthesis. Used for Community-acquired pneumonia, Skin and soft tissue infections, Urinary tract infections.
At a glance
| Generic name | Standard of Care Antibiotics |
|---|---|
| Also known as | Antibiotics |
| Sponsor | Rebiotix Inc. |
| Drug class | Antibiotic |
| Target | Bacterial cell wall enzymes or proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
They do this by targeting specific bacterial enzymes or proteins, ultimately leading to the death of the bacterial cell. This can be achieved through various mechanisms, such as inhibiting cell wall synthesis or interfering with protein synthesis.
Approved indications
- Community-acquired pneumonia
- Skin and soft tissue infections
- Urinary tract infections
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection (NA)
- Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (PHASE2)
- Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision (NA)
- Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial (NA)
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- PMPR and Chlorhexidine on Periodontal Disease and Vascular Function (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard of Care Antibiotics CI brief — competitive landscape report
- Standard of Care Antibiotics updates RSS · CI watch RSS
- Rebiotix Inc. portfolio CI
Frequently asked questions about Standard of Care Antibiotics
What is Standard of Care Antibiotics?
How does Standard of Care Antibiotics work?
What is Standard of Care Antibiotics used for?
Who makes Standard of Care Antibiotics?
Is Standard of Care Antibiotics also known as anything else?
What drug class is Standard of Care Antibiotics in?
What development phase is Standard of Care Antibiotics in?
What are the side effects of Standard of Care Antibiotics?
What does Standard of Care Antibiotics target?
Related
- Drug class: All Antibiotic drugs
- Target: All drugs targeting Bacterial cell wall enzymes or proteins
- Manufacturer: Rebiotix Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Community-acquired pneumonia
- Indication: Drugs for Skin and soft tissue infections
- Indication: Drugs for Urinary tract infections
- Also known as: Antibiotics
- Compare: Standard of Care Antibiotics vs similar drugs
- Pricing: Standard of Care Antibiotics cost, discount & access